Numab Therapeutics raised $55M in a Series C funding round co-led by Cormorant Asset Management and Forbion to develop multi-specific antibody-based immunotherapies.
Amount Raised
$55 Million
Round Type
Series C
Investors
Description
Biotech Numab Therapeutics has successfully raised $55 million, increasing its total Series C fundraise to $197 million. The funding will support the development of its innovative modular platform for antibody-based therapies targeting inflammation and cancer.
Quick answer
Numab Therapeutics raised $55 Million in a Series C round, dated January 10, 2025. Investors: Blackrock, Hbm Healthcare Investment, Novo Holdings, BVF Partners LP, Octagon Capital Advisors Lp, RTW Investments, Cormorant Asset Management and Forbion.
- How much did Numab Therapeutics raise?
- Numab Therapeutics raised $55 Million in a Series C round on January 10, 2025.
- Who invested in Numab Therapeutics?
- Blackrock, Hbm Healthcare Investment, Novo Holdings, BVF Partners LP, Octagon Capital Advisors Lp, RTW Investments, Cormorant Asset Management and Forbion are named as investors in this round.
- What does Numab Therapeutics do?
- Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer.
- Where is Numab Therapeutics based and how big is it?
- Fundz records about 68 employees.
- Who are the decision-makers at Numab Therapeutics?
- Fundz holds 1 contact at Numab Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Numab Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Solid IO raised $839K (Seed) on February 24, 2025.
- Humane Genomics raised an undisclosed amount (Seed) on February 21, 2025.
- Ceretas raised $1M (Seed) on February 21, 2025.
- Reverb Therapeutics raised $12M (Seed) on February 19, 2025.
- MAIA Biotechnology raised $4.1M (Seed) on February 18, 2025.
- Bambusa Therapeutics raised $90M (Series A) on February 14, 2025.
Who to call at Numab Therapeutics, and when
A new round usually means Numab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Numab Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Numab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Numab Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Numab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Numab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.